Article3 Biotech2024
Jumonji and AT-Rich Interacting Domain 2 (JARID2) exhibits a tumor-suppressive role in Oral Squamous Cell Carcinoma by modulating tumor progression and metastasis.
Article in 3 Biotech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Jumonji and AT Rich Interacting Domain2 (JARID2), a pivotal accessory component of Polycomb Repressive Complex 2 (PRC2) is a critical factor in cancer development. The objective of the study was to determine the role of JARID2 in Oral Squamous Cell Carcinoma (OSCC). RT-PCR, qRT-PCR, immunofluorescence, immunohistochemistry, and western blot were used to analyze the gene and protein expression in OSCC clinical samples and OSCC cell lines. The experiments have collectively demonstrated the downregulation of JARID2 mRNA and protein expression during OSCC metastasis. The cytoplasmic localization of JARID2 in OSCC tissues and cell lines were also observed. In addition, JARID2 was knocked down in HSC-3 cells by performing siRNA-mediated transfection which revealed an increase in the expression of mesenchymal markers, N-cadherin and vimentin, and a downregulation of epithelial marker E-cadherin. Moreover, silencing JARID2 significantly increased the metastatic features such as migration, invasion, and colony-formation ability in HSC-3 cells. Also, the knockdown significantly reduced the number of apoptotic cells, suggesting that JARID2 knockdown has critically promoted HSC-3 cell metastasis by enhancing the mesenchymal markers. Taken together, the study has confirmed that JARID2 acts as a tumor suppressor, the downregulation of which promotes OSCC progression by regulating Epithelial-to-Mesenchymal Transition (EMT). Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-024-04163-8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.